BRISTOL-MYERS SQUIBB COMPANY Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 1.00 million shares for the 6-month period ending 2015-06-30, per its 10-Q filed 2016-07-28.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2017-02-21
- BRISTOL-MYERS SQUIBB COMPANY incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2014-09-30 was 1.00M shares, a 0.00% change year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2014-06-30 was 1.00M shares, a 0.00% change year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2014-03-31 was 1.00M shares, a 0.00% change year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2013-09-30 was 1.00M shares.
- BRISTOL-MYERS SQUIBB COMPANY incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2014 was 1.00M shares, a 0.00% change from fiscal 2013.
- BRISTOL-MYERS SQUIBB COMPANY incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2013 was 1.00M shares, a 0.00% change from fiscal 2012.
- BRISTOL-MYERS SQUIBB COMPANY incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2012 was 1.00M shares, a 0.00% change from fiscal 2011.
- BRISTOL-MYERS SQUIBB COMPANY incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2011 was 1.00M shares, a 0.00% change from fiscal 2010.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|---|
| 2015-06-30 | 1.00M shares 10-Q · filed 2016-07-28 | |||
| 2014-12-31 | 1.00M shares 10-K · filed 2017-02-21 | |||
| 2014-09-30 | 1.00M shares 10-Q · filed 2015-10-27 | 1.00M shares 10-Q · filed 2015-10-27 | ||
| 2014-06-30 | 1.00M shares 10-Q · filed 2015-07-23 | 1.00M shares 10-Q · filed 2015-07-23 | ||
| 2014-03-31 | 1.00M shares 10-Q · filed 2015-04-28 | |||
| 2013-12-31 | 1.00M shares 10-K · filed 2016-02-12 | |||
| 2013-09-30 | 1.00M shares 10-Q · filed 2014-10-24 | 1.00M shares 10-Q · filed 2014-10-24 | ||
| 2013-06-30 | 1.00M shares 10-Q · filed 2014-07-24 | 1.00M shares 10-Q · filed 2014-07-24 | ||
| 2013-03-31 | 1.00M shares 10-Q · filed 2014-04-29 | |||
| 2012-12-31 | 1.00M shares 10-K · filed 2015-02-13 | |||
| 2012-09-30 | 1.00M shares 10-Q · filed 2013-10-23 | |||
| 2012-06-30 | 1.00M shares 10-Q · filed 2013-07-25 | 1.00M shares 10-Q · filed 2013-07-25 | ||
| 2012-03-31 | 1.00M shares 10-Q · filed 2013-04-25 | |||
| 2011-12-31 | 1.00M shares 10-K · filed 2014-02-14 | |||
| 2011-09-30 | 1.00M shares 10-Q · filed 2012-10-24 | 1.00M shares 10-Q · filed 2012-10-24 | ||
| 2011-06-30 | 1.00M shares 10-Q · filed 2012-07-25 | 1.00M shares 10-Q · filed 2012-07-25 | ||
| 2011-03-31 | 1.00M shares 10-Q · filed 2012-04-26 | |||
| 2010-12-31 | 1.00M shares 10-K · filed 2013-02-15 | |||
| 2010-09-30 | 1.00M shares 10-Q · filed 2011-10-27 | 1.00M shares 10-Q · filed 2011-10-27 | ||
| 2010-06-30 | 1.00M shares 10-Q · filed 2011-07-28 | 1.00M shares 10-Q · filed 2011-07-28 | ||
| 2009-12-31 | 1.00M shares 10-K · filed 2012-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |